scholarly journals The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent

2014 ◽  
Vol 15 (5) ◽  
pp. 7213-7224 ◽  
Author(s):  
Roberta D'Ambrosio ◽  
Alessio Aghemo ◽  
Raffaele De Francesco ◽  
Maria Rumi ◽  
Enrico Galmozzi ◽  
...  
2013 ◽  
Vol 45 ◽  
pp. S8
Author(s):  
R. D'Ambrosio ◽  
A. Aghemo ◽  
R. De Francesco ◽  
M.G. Rumi ◽  
E. Galmozzi ◽  
...  

2010 ◽  
Vol 48 (05) ◽  
Author(s):  
A Staettermayer ◽  
K Rutter ◽  
S Beinhardt ◽  
TM Scherzer ◽  
K Zinober ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (7) ◽  
pp. e20904 ◽  
Author(s):  
Thomas R. O'Brien ◽  
James E. Everhart ◽  
Timothy R. Morgan ◽  
Anna S. Lok ◽  
Raymond T. Chung ◽  
...  

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 45B-48B ◽  
Author(s):  
Stephanos J Hadziyannis

Chronic hepatitis C (CHC) is a major health problem worldwide, with approximately 200 million affected individuals and a significant rate of progression to end-stage cirrhosis and hepatocellular carcinoma (HCC). If hepatitis C virus (HCV) infection is left untreated in the population, then the number of liver-related deaths will soon double and the need for liver transplantation may increase to five times that seen today. Available therapies for CHC are restricted to interferon alpha (IFN-α ) monotherapy and to the combination of IFN-α and ribavirin. Despite their high cost and side effects, both of these therapies have proved to be cost effective, particularly combination therapy. IFN-α monotherapy for one year can induce sustained response (SR) rates of approximately 10% in naive patients infected with HCV genotype 1, and above 50% in those infected with other genotypes. Combination therapy can double or even triple the rate of SR in genotype 1 infections and may further increase the SR rate in the other HCV genotypes. Combination therapy has also been proven to be effective in approximately 50% of relapsed responders to IFN-α monotherapy. In clinical practice, the decision to treat should be individualized and tailored on the basis of several virus- and host-related factors, particularly the grade and stage of liver disease, HCV genotype and levels of viremia. Appropriate monitoring of therapy by careful clinical evaluation, liver biochemistry and serumHCVRNAtesting is mandatory. IFN-α therapy may also prove to be effective in reducing the rate of HCC development in CHC regardless of whether a virological response is achieved, but this remains to be established.


2011 ◽  
Vol 54 (6) ◽  
pp. 1123-1129 ◽  
Author(s):  
Charlotte E. Costentin ◽  
Françoise Roudot-Thoraval ◽  
Elie-Serge Zafrani ◽  
Fatiha Medkour ◽  
Jean-Michel Pawlotsky ◽  
...  

2001 ◽  
Vol 13 (5) ◽  
pp. 501-506 ◽  
Author(s):  
Luigi Roffi ◽  
Alessandro Redaelli ◽  
Guido Colloredo ◽  
Eliseo Minola ◽  
Carlo Donada ◽  
...  

2019 ◽  
Vol 49 ◽  
Author(s):  
Irma Salimović- Bešić ◽  
Adna Kahriman ◽  
Suzana Arapčić ◽  
Amela Dedeić- Ljubović

Background: Hepatitis C virus (HCV) genotypes and subtypes exhibit significant geographic variations.Aim: To analyse the distribution of genotypes/subtypes of HCV in a group of patients with chronic hepatitis C from Canton Sarajevo during 2012-2018.Material and methods:The study enrolled 247 human plasma samples of HCV-RNA positive patients with available results of HCV genotyping test.Results: During 2012-2018, the domination of subtypes 1a (34.01%), 1b (28.34%) and genotype 3 (23.89%) was registered. In 2012 and 2013, HCV subtype 1a was the most common (27/63; 42.86% and 17/40; 42.50%, respectively). In 2014, the leading HCV genotype/subtype were 3 and 1b (17/57; 29.82%). In 2015, the dominance of HCV genotype 3 (14/39; 35.90%) continued, while in 2016, the same number of HCV subtypes 1a and 1b (11/30; 36.67%) was recorded. Although in a small number of tested, during 2017, HCV subtype 1b was the most prevalent (7/14; 50.00%), and in 2018, it was replaced by a HCV subtype 1a (3/4; 75.00%). Distribution of HCV genotypes/subtypes by age group of patients varied significantly (p=0.000). The largest number of patients (71/247; 28.74%) belonged to the age category 30-39 years and HCV genotypes/subtypes 1, 3, 4, 1a and 1b were identified. Except in 2017, male gender significantly dominated (p=0.000). In males, HCV subtype 1a (68/170; 40.00%) was the most common, while in women it was HCV subtype 1b (44/77; 57.14%).Conclusion: This six-year retrospective study showed the time variations of the circulating HCV genotypes/subtypes among patients with chronic hepatitis C in Canton Sarajevo. Genotyping of the HCV has an important implications for diagnosis and treatment of the patients.


Sign in / Sign up

Export Citation Format

Share Document